- Adamas has become much less exciting the last few years with sales of GOCOVRI slowing in its second year.
- They decided to give up on attempting to treat the walking speed in those with Multiple Sclerosis with GOCOVRI after lackluster results.
- Hope remains with a new CEO, Neil McFarlane, in 2019 who has done very well cutting costs while accelerating growth of revenues.
- I predict they will make it to cash flow positive in 2022, so their value will be determined by what peak sales are looking like.
For further details see:
Adamas: How We Got Here And What The Future Brings